Program
soquelitinib
Also written as “Soquelitinib” and “CPI-818”.
Its studies are mostly in Lymphoma, T-Cell · Dermatitis, Atopic · Hidradenitis Suppurativa, led by Corvus Pharmaceuticals.
Furthest: phase 3, since Aug 16, 20245 company-led studies, 4 open or runningNext primary completion: Dec 30, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Corvus Pharmaceuticals | 54 open or running | phase 3since Aug 16, 2024 | May 7, 2019 | Dec 30, 2026phase 1 · NCT03952078 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 7, 2019First study: phase 1 study in Lymphoma, T-CellFirst studyNCT03952078 · 151 enrolled · United States, Australia, China and more
- Mar 12, 2024Phase 1 study in Dermatitis, AtopicNCT06345404 · 82 enrolled · United States
- Aug 16, 2024Phase 3 study in Lymphoma, T-CellNCT06561048 · 150 planned · United States, Australia, Canada
- Feb 23, 2026Phase 2 study in Dermatitis, AtopicNCT07441395 · 200 planned · United States
- Sep 3, 2026Phase 1 study in Hidradenitis SuppurativaNCT07828860 · 25 planned · United States
Ahead
- Dec 30, 2026Primary completion: phase 1 study in Lymphoma, T-CellNCT03952078
- Jun 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07441395
- Nov 2027Primary completion: phase 3 study in Lymphoma, T-CellNCT06561048
- Dec 2027Primary completion: phase 1 study in Hidradenitis SuppurativaNCT07828860
TargetBeta
ITK →read by rule
“An orally available, small-molecule, irreversible inhibitor of interleukin-2 inducible T-cell kinase (ITK) ”NCIt, by rule
Other programs on ITK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ritlecitinibrule | Pfizer | phase 3 | 42 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07828860Hidradenitis Suppurativa · United States | 1 | Recruiting | Dec 2027 | 25 |
| NCT07441395Dermatitis, Atopic · United States | 2 | Recruiting | Jun 2027 | 200 |
| NCT06561048Lymphoma, T-Cell · United States, Australia, Canada | 3 | Recruiting | Nov 2027 | 150 |
| NCT06345404Dermatitis, Atopic · United States | 1 | Completed | Jan 28, 2026 | 82 |
| NCT03952078Lymphoma, T-Cell · United States, Australia, China and more | 1 | Active, not recruiting | Dec 30, 2026 | 151 |
How it is read
Names in the registry
- “Soquelitinib”, 4 entries
- “CPI-818”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, T-Cell, 2 studies
- Dermatitis, Atopic, 2 studies
- Hidradenitis Suppurativa, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.